Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health.
The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s platform technologies vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials.
With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation enabling the next generation of medicines by delivering genome editing at an unprecedented scale.
Genome engineering, accessible to all
Synthego was founded to revolutionize genome engineering technology, helping translate genomics into the clinic and ultimately making engineered biological therapies accessible to all patients.
Synthego’s mission is to enable agile life science research and development from discovery through clinical introduction by providing scientists unprecedented access to advanced genome engineering products at high throughput.
Featured Resource
CRISPR Overview: Essential Resources
CRISPR is a revolutionary tool in the world of genome editing. However, while it may seem like a magic bullet, CRISPR experiments are not easy. A small misstep in design or optimization can lead to researchers spending weeks and months on trial and error without editing success.
No need to waste any more time. Synthego has brought together the best resources to help you get CRISPR right the first time!
Synthego’s vision for automating biological research will revolutionize the industry by accelerating application development and enabling machine learning based insights. Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach. I look forward to contributing to the company’s success as the business extends further into the genome engineering market.
